ANI Pharmaceuticals (NASDAQ:ANIP) Rating Reiterated by Guggenheim

Guggenheim reiterated their buy rating on shares of ANI Pharmaceuticals (NASDAQ:ANIP) in a research report report published on Tuesday, Benzinga reports. The firm currently has a $77.00 target price on the specialty pharmaceutical company’s stock.

Several other research firms have also commented on ANIP. Truist Financial raised their price objective on ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a buy rating in a research report on Friday, March 1st. Capital One Financial started coverage on ANI Pharmaceuticals in a research report on Friday, March 15th. They issued an overweight rating and a $80.00 price objective on the stock. Finally, HC Wainwright raised their price objective on ANI Pharmaceuticals from $73.00 to $83.00 and gave the company a buy rating in a research report on Monday, March 4th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of Buy and a consensus price target of $80.00.

ANI Pharmaceuticals Price Performance

ANIP stock opened at $66.14 on Tuesday. ANI Pharmaceuticals has a 52-week low of $36.99 and a 52-week high of $70.81. The stock’s fifty day simple moving average is $65.12 and its 200-day simple moving average is $58.70. The company has a quick ratio of 2.81, a current ratio of 3.57 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of 78.74 and a beta of 0.79.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. The business had revenue of $131.65 million for the quarter, compared to analysts’ expectations of $123.02 million. Equities research analysts expect that ANI Pharmaceuticals will post 3.55 EPS for the current year.

Insider Activity

In related news, CFO Stephen P. Carey sold 7,787 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $65.55, for a total transaction of $510,437.85. Following the sale, the chief financial officer now owns 177,712 shares of the company’s stock, valued at $11,649,021.60. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 28,965 shares of the company’s stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $65.52, for a total value of $1,897,786.80. Following the transaction, the chief executive officer now owns 444,981 shares of the company’s stock, valued at $29,155,155.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Stephen P. Carey sold 7,787 shares of the company’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $65.55, for a total value of $510,437.85. Following the completion of the transaction, the chief financial officer now directly owns 177,712 shares in the company, valued at approximately $11,649,021.60. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 156,803 shares of company stock valued at $10,363,466. Insiders own 12.70% of the company’s stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in shares of ANI Pharmaceuticals by 5.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,132,378 shares of the specialty pharmaceutical company’s stock valued at $65,746,000 after acquiring an additional 58,204 shares in the last quarter. Rubric Capital Management LP grew its holdings in shares of ANI Pharmaceuticals by 32.8% during the 4th quarter. Rubric Capital Management LP now owns 1,125,000 shares of the specialty pharmaceutical company’s stock valued at $62,032,000 after acquiring an additional 277,989 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of ANI Pharmaceuticals by 6.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 591,731 shares of the specialty pharmaceutical company’s stock valued at $32,628,000 after acquiring an additional 33,359 shares in the last quarter. Global Alpha Capital Management Ltd. grew its holdings in shares of ANI Pharmaceuticals by 10.8% during the 4th quarter. Global Alpha Capital Management Ltd. now owns 582,428 shares of the specialty pharmaceutical company’s stock valued at $32,115,000 after acquiring an additional 56,900 shares in the last quarter. Finally, Ranger Investment Management L.P. grew its holdings in shares of ANI Pharmaceuticals by 1.8% during the 4th quarter. Ranger Investment Management L.P. now owns 434,617 shares of the specialty pharmaceutical company’s stock valued at $23,965,000 after acquiring an additional 7,769 shares in the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.